The estimated Net Worth of Vikas Sinha is at least $18.5 Millón dollars as of 19 August 2024. Mr Sinha owns over 3,159 units of AlloVir stock worth over $876,724 and over the last 19 years he sold ALVR stock worth over $16,943,823. In addition, he makes $654,900 as Pres y CFO & Director at AlloVir.
Mr has made over 89 trades of the AlloVir stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 3,159 units of ALVR stock worth $2,401 on 19 August 2024.
The largest trade he's ever made was exercising 75,000 units of AlloVir stock on 2 December 2014 worth over $1,407,000. On average, Mr trades about 7,731 units every 55 days since 2005. As of 19 August 2024 he still owns at least 1,153,584 units of AlloVir stock.
You can see the complete history of Mr Sinha stock trades at the bottom of the page.
Vikas Sinha C.A., CPA, M.B.A. is the Pres, CFO & Director at AlloVir.
As the Pres y CFO & Director of AlloVir, the total compensation of Mr A at AlloVir is $654,900. There are 1 executives at AlloVir getting paid more, with David L. Hallal having the highest compensation of $981,018.
Mr A is 58, he's been the Pres y CFO & Director of AlloVir since . There are no older and 9 younger executives at AlloVir.
Vikas's mailing address filed with the SEC is C/O ALLOVIR, INC., P.O. BOX 44, 1661 MASSACHUSETTS AVE., LEXINGTON, MA, 02420.
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... y Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
AlloVir executives and other stock owners filed with the SEC include: